APC is altered in 8.59% of esophageal adenocarcinoma patients [2].

APC is an inclusion eligibility criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains APC status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

ARID1A is altered in 14.85% of esophageal adenocarcinoma patients [2].

ARID1A is an inclusion eligibility criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ARID1A status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ATM is altered in 3.9% of esophageal adenocarcinoma patients [2].

ATM is an inclusion eligibility criterion in 2 clinical trials for esophageal adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain ATM status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

ATR is altered in 2.62% of esophageal adenocarcinoma patients [2].

ATR is an inclusion eligibility criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ATR status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

BARD1 is altered in 1.83% of esophageal adenocarcinoma patients [2].

BARD1 is an inclusion eligibility criterion in 2 clinical trials for esophageal adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain BARD1 status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

BRCA1 is altered in 2.95% of esophageal adenocarcinoma patients [2].

BRCA1 is an inclusion eligibility criterion in 2 clinical trials for esophageal adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain BRCA1 status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

BRCA2 is altered in 5.12% of esophageal adenocarcinoma patients [2].

BRCA2 is an inclusion eligibility criterion in 2 clinical trials for esophageal adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain BRCA2 status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

BRIP1 is altered in 2.17% of esophageal adenocarcinoma patients [2].

BRIP1 is an inclusion eligibility criterion in 2 clinical trials for esophageal adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain BRIP1 status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

BTRC is an inclusion eligibility criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains BTRC status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

CDK12 is altered in 8.95% of esophageal adenocarcinoma patients [2].

CDK12 is an inclusion eligibility criterion in 2 clinical trials for esophageal adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain CDK12 status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

CHEK1 is altered in 0.53% of esophageal adenocarcinoma patients [2].

CHEK1 is an inclusion eligibility criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains CHEK1 status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

CHEK2 is altered in 1.29% of esophageal adenocarcinoma patients [2].

CHEK2 is an inclusion eligibility criterion in 2 clinical trials for esophageal adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain CHEK2 status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

CTNNB1 is altered in 3.78% of esophageal adenocarcinoma patients [2].

CTNNB1 is an inclusion eligibility criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains CTNNB1 status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

DDX3X is an inclusion eligibility criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains DDX3X status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

DVL1 is an inclusion eligibility criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains DVL1 status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

ERBB2 is altered in 19.0% of esophageal adenocarcinoma patients [2].

ERBB2 is an inclusion eligibility criterion in 11 clinical trials for esophageal adenocarcinoma, of which 11 are open and 0 are closed. Of the trials that contain ERBB2 status and esophageal adenocarcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), and 7 are phase 2 (7 open) [3].

FANCA is altered in 2.83% of esophageal adenocarcinoma patients [2].

FANCA is an inclusion eligibility criterion in 2 clinical trials for esophageal adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain FANCA status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

FANCB is altered in 0.61% of esophageal adenocarcinoma patients [2].

FANCB is an inclusion eligibility criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCB status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FANCC is altered in 1.15% of esophageal adenocarcinoma patients [2].

FANCC is an inclusion eligibility criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCC status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FANCD2 is altered in 2.38% of esophageal adenocarcinoma patients [2].

FANCD2 is an inclusion eligibility criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCD2 status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FANCE is altered in 1.92% of esophageal adenocarcinoma patients [2].

FANCE is an inclusion eligibility criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCE status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FANCF is altered in 0.81% of esophageal adenocarcinoma patients [2].

FANCF is an inclusion eligibility criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCF status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FANCG is altered in 1.62% of esophageal adenocarcinoma patients [2].

FANCG is an inclusion eligibility criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCG status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FANCI is altered in 2.25% of esophageal adenocarcinoma patients [2].

FANCI is an inclusion eligibility criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCI status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FANCL is altered in 2.31% of esophageal adenocarcinoma patients [2].

FANCL is an inclusion eligibility criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCL status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FANCM is altered in 6.1% of esophageal adenocarcinoma patients [2].

FANCM is an inclusion eligibility criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCM status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FZD1 is an inclusion eligibility criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD1 status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FZD10 is an inclusion eligibility criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD10 status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FZD2 is an inclusion eligibility criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD2 status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FZD3 is an inclusion eligibility criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD3 status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FZD4 is an inclusion eligibility criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD4 status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FZD5 is an inclusion eligibility criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD5 status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FZD6 is an inclusion eligibility criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD6 status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FZD7 is an inclusion eligibility criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD7 status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FZD8 is an inclusion eligibility criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD8 status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FZD9 is an inclusion eligibility criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD9 status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

GEN1 is altered in 1.21% of esophageal adenocarcinoma patients [2].

GEN1 is an inclusion eligibility criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains GEN1 status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

KMT2D is altered in 8.76% of esophageal adenocarcinoma patients [2].

KMT2D is an inclusion eligibility criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains KMT2D status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

LRP5 is an inclusion eligibility criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains LRP5 status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

LRP6 is an inclusion eligibility criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains LRP6 status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MCPH1 is an inclusion eligibility criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MCPH1 status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MRE11A is altered in 1.61% of esophageal adenocarcinoma patients [2].

MRE11A is an inclusion eligibility criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MRE11A status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MYC is altered in 8.63% of esophageal adenocarcinoma patients [2].

MYC is an inclusion eligibility criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MYC status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

NBN is altered in 2.09% of esophageal adenocarcinoma patients [2].

NBN is an inclusion eligibility criterion in 2 clinical trials for esophageal adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain NBN status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

PALB2 is altered in 1.69% of esophageal adenocarcinoma patients [2].

PALB2 is an inclusion eligibility criterion in 2 clinical trials for esophageal adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain PALB2 status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

PTEN is altered in 2.56% of esophageal adenocarcinoma patients [2].

PTEN is an inclusion eligibility criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

RAD50 is altered in 1.93% of esophageal adenocarcinoma patients [2].

RAD50 is an inclusion eligibility criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD50 status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

RAD51 is altered in 0.87% of esophageal adenocarcinoma patients [2].

RAD51 is an inclusion eligibility criterion in 2 clinical trials for esophageal adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain RAD51 status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

RAD51B is an inclusion eligibility criterion in 2 clinical trials for esophageal adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain RAD51B status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

RAD51C is altered in 0.77% of esophageal adenocarcinoma patients [2].

RAD51C is an inclusion eligibility criterion in 2 clinical trials for esophageal adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain RAD51C status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

RAD51D is altered in 0.58% of esophageal adenocarcinoma patients [2].

RAD51D is an inclusion eligibility criterion in 2 clinical trials for esophageal adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain RAD51D status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

RAD54L is altered in 0.3% of esophageal adenocarcinoma patients [2].

RAD54L is an inclusion eligibility criterion in 2 clinical trials for esophageal adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain RAD54L status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

SLX4 is altered in 2.92% of esophageal adenocarcinoma patients [2].

SLX4 is an inclusion eligibility criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains SLX4 status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

SMARCA4 is altered in 8.59% of esophageal adenocarcinoma patients [2].

SMARCA4 is an inclusion eligibility criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains SMARCA4 status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

TP53 is altered in 79.98% of esophageal adenocarcinoma patients [2].

TP53 is an inclusion eligibility criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains TP53 status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

WNT1 is an inclusion eligibility criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains WNT1 status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].